Special Issue

Emergency and Critical Care in the Context of Personalized Medicine

Message from the Guest Editors

Critically ill patients are currently framed within very complex algorithms and protocols, the furthest thing from personalized medicine. This happens when critical medicine tries to use the results of large trials and available guidelines to obtain the best possible outcome. However, not all fit for all patients. Protective ventilation can differ depending on the initial quality of the lungs. The management of sepsis and temperature are closely linked to the individual metabolism of the patient. Beyond the macroscopic therapeutic differences between adult and pediatric patients, today it is increasingly essential to "measure" the intensity of care also on the wishes expressed for well-being by the patient, or to consider what degree of disability the patient and his caregivers can consider acceptable after extremely critical pathological conditions. This Special Issue is dedicated to all the literature, which focuses on the aspects of tailored critical care. Journal articles. reviews, and communications are welcomed.

Guest Editors

Dr. Raffaele Aspide IRCCS Istituto delle Scienze Neurologiche di Bologna, Anesthesia and Neurointensive Care Unit, Bologna, Italy

Prof. Dr. Daniele Biasucci

Department of Clinical Science and Translational Medicine, "Tor Vergata" University of Rome, 00133 Rome, Italy

Deadline for manuscript submissions

25 December 2024

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/205243

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).